Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies focused on the treatment and diagnosis of cancer. Peregrine is pursuing multiple clinical programs in cancer with its lead product candidate, bavituximab, and novel brain cancer agent Cotara. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for Peregrine and outside customers. Bavituximab in combination with chemotherapy has demonstrated promising signs of anti-tumor activity and survival trends in patients with non-small cell lung cancer (NSCLC) and advanced breast cancer. For more information, visit the company’s website at www.peregrineinc.com